Summer Newsletter
February 2001,
Number 8
EDITORIAL.
Now we are in the third millennium by everyone's reckonings,
welcome back to this newsletter. I hope you all had a satisfying
holiday, whatever you managed to do. The year is flashing by as
we are getting towards the end of February already, which last
year was declared to be Age-related Macular Degeneration and Low
Vision Awareness month by the American Academy of
Ophthalmologists. To recognise the importance of this, the
Foundation for the Blind has advertised for a Divisional Manager
to head their newly created Blindness Awareness & Prevention
Division.
With this newsletter all those members with an inherited retinal
degeneration are being sent a newly published and updated booklet
of "A Family Affair - a New Zealand Guide to Inherited Retinal
Degeneration", published by Retina New Zealand. This new Guide
is right up-to-date with current knowledge of these disorders.
Members with Age-related Macular Degeneration will have to wait
a little longer. A booklet on Age-related macular degeneration
is currently being drafted and when this is published, members
with macular degeneration will be sent a copy with their
newsletter.
During the Christmas break I read the two books on macular
degeneration featured in our last newsletter as being available
on tape from the RNZFB Talking Book Library and I highly
recommend TB6668 - "Macular Degeneration: the complete guide to
saving and maximising your sight" by Lylas Moqk, MD and Maria
Moqk. The other book by Betty Wason is written for Americans to
read and does not relate well to New Zealand.
After briefly shining a light into the eye with the splinter she
casually said "You have Retinitis Pigmentosa and you are losing
your sight. You had better make an appointment with an
ophthalmologist!".
Your membership is due for renewal on 1st April, 2001 and we are
enclosing a membership renewal form for you to complete and
return with your cheque. Please post date the cheque to 2nd
April, 2001 so that it appears in next year's accounts.
As this newsletter goes to press it has just been announced over
the news that two papers have been published simultaneously in
the prestigious magazines "Science" and "Nature" by the two rival
groups identifying the human genome. Both of them come to the
same conclusion independently - that the human genome consists
of around 30,000 genes, far fewer than previously suggested. So
man is a less complex creature than previously believed and only
has a few more genes than the mouse! This will speed up genetic
research into all sorts of diseases, including age-related
macular degeneration.
We need more writers of articles for this newsletter. How about
writing about yourself or a member you admire in your branch for
our 'People' section, or an article on how you cope with a
difficult problem, e.g. staying in a strange hotel on your own.
We always need more letters to the Editor on anything that
bothers you or that you feel will be useful to other members.
Perhaps this society or another member can help you.
June Ombler 207 Forbury Road, St Clair,
Dunedin Phone (03) 455 8813
Email: jombler@xtra.co.nz
FROM THE PRESIDENT'S DESK by Anthony Haas
Retina New Zealand's strategy to reach out to others interested
in what we are learning about coping with challenges to the back
of the eye is being implemented. It is drawing on the strengths
of younger people, and makes it easier for individuals to work
with their branches to share their experiences.
Peer support
Elizabeth East has been appointed National Co-ordinator for our
Peer Support Programme, following the training workshop and
development work carried by the chair of the Wellington branch,
Pat Nicholson. Elizabeth's background and programme planning
will be a useful part of future newsletters as she pulls us
together, so that the dozen initial peer supporters we have
brought to the fore can help callers on the phone.
The peer support programme's relationship to RNZFB activities and
experience will be explored when Elizabeth joins the Retina New
Zealand and Consumer consultations in Auckland in April - helping
us all to work as a team to help those who want to talk with
their peers about the challenges they are encountering.
Public Education
The 2001 edition of "A Family Affair" - A New Zealand Guide to
Inherited Retinal Degenerations - has been printed. It has an
outside back page advertisement promoting our peer support
through the RNZFB 0800 number, so that the consumers and
professionals who get sent their copies of the 1000 we have
printed will be able to help promote the peer support programme.
We are sending a covering letter to our audience telling of the
peer support programme.
This and more information will be able to be promoted on the
Retina NZ website (www.retina.org.nz) that Fraser Alexander,
chair of our Auckland branch, is building up for us. People who
want peer support, or just to find us through their own internet
use, should be able to get more and more information on retinal
dystrophies as a result of our website content and the links from
it to other relevant useful websites throughout the world. Our
public education is not forgetting the print and other media -
the Dunedin branch chair Helen Adams is co-ordinating the
drafting team that is producing an even more consumer friendly
booklet on macular degeneration.
Research
The Dunedin branch has also been asked to help formulate a
research strategy for Retina New Zealand. Funds from outside the
RNZFB have been raised from New Zealand and from international
sources to support research and blindness prevention - an
approach that might also help Retina New Zealand in its relations
with those who are reserved about RNZFB funds being used on these
activities.
Administration
Our Christchurch based vice president Kaye Newton has drawn
together Retina New Zealand's budget proposal to the RNZFB for
our grant request for the year from mid 2001. It proposes
continuation of our peer support, public education and
administrations programme - and is a transparent framework within
which our membership and the RNZFB can propose desired continuity
and change. Each programme is led by one of our four branches
- and allows for branches and members to contract to implement
projects in these programmes.
Policy and external relations
Kaye Clark, our Wellington based policy secretary continues her
monitoring of and input to the fast moving disability and health
strategy and government administration process. Executive
members have represented Retina New Zealand in meetings with
other agencies such as the Disabled Persons Assembly - and the
pace of dialogue will step up again as our delegation assembles
in Auckland around ANZAC day to talk with the RNZFB managers and
other consumer organisations from the Association of Blind
Citizens to Parents of the Vision Impaired.
Our reaching out programme is unfinished - and our work
programmes provide us with more substance to offer to others.
My thanks to those who contribute their voluntary effort and
professionalism to help people we should strive to help to hope
and cope.
EXCITING NEWS FOR ALL OF US From Professor Gislin Dagnelie, Ph.D,
Lions Vision Research & Rehab. Centre, Johns Hopkins University,
Baltimore USA.
The National Eye Institute announced the name of its new director
yesterday, and he is none other than Paul Sieving, currently a
professor of ophthalmology in Ann Arbor, Michigan. Yes, indeed,
the husband of Pam Sieving, who so generously compiles for us a
monthly reference list of published papers in the field of
retinal degenerations.
I have known Paul for over 20 years through the International
Society for Clinical Electrophysiology of Vision (the group of
researchers and clinicians that establishes guidelines for the
use of electroretinograms and visually evoked potentials, among
other things), and that is just one of the many groups in which
Paul has been very active. He has also been very active in the
Foundation Fighting Blindness (I believe he is currently the
chair of the FFB's Scientific Advisory Board), and brings a lot
of FFB enthusiasm into the National Eye Institute.
Most of all, he is a wonderful clinician, a researcher with a
broad area of expertise in the genetics of retinal degenerations
and other eye diseases, but also an expert in psychophysics
(measuring vision) and, as I said, electrophysiology. In
addition, he has a law degree so he understands a lot about
making policy, setting guidelines (as he has done in ISCEV and
the FFB), etc. He has great empathy with his patients, and
understands what those suffering from vision loss through eye
disease are going through.
Why is all this important to us? In case you don't know, the
National Eye Institute is the branch of the National Institutes
of Health that funds research and sets policies in the area of
eye disease. Although the director is far from alone in setting
policies, and although the grant review process is completely out
of his control, indirectly he has a lot of influence over the
long-term direction of eye research in the US. Having someone
there with a strong background in retinal degenerative diseases
can be of great help to us in the long run, if only because he
will give the NEI a strong voice when it comes to setting budget
priorities in the US Congress, using age-related eye disease, and
vision loss due to degenerative eye diseases as strong arguments
for further funding increases in eye research.
RESEARCH
GENETIC DISCOVERIES IN THE NEWS From US FFB Executive News,
January 2001
Foundation researchers are discovering genes with mutations that
cause retinal degeneration at an ever-increasing pace. Over the
last two months researchers have identified several new mutant
genes causing RP, macular degeneration and Usher syndrome three
of which are described below.
1. Gene Mutation causing RP found in humans and rodent
Drs Andreas Gal, Samuel Jacobson and Donald Volrath who led the
original research effort an international team of vision
researchers, discovered mutations in the Mertk gene that causes
a severe, early-onset form of retinitis pigmentosa (RP). The
stimulus to seek the gene mutations was the recent discovery that
a Mertk gene mutation is responsible for RP in a well-known
animal model called the Royal College of Surgeons (RCS) rat.
The RCS rat has been used successfully in numerous studies
testing experimental transplant and pharmaceutical therapies.
Animal models of human disease are critical to developing and
testing experimental therapies. Discovery of Mertk mutations in
humans allows researchers to better understand the causes of
retinal degeneration and validates the importance of the RCS rat
as a valuable animal model of human disease.
Mertk gene involved in Outer Segment Recycling
The Mertk gene and its protein product are active in a layer of
cells that adjoin photoreceptor cells called the retinal pigment
epithelium (RPE). RPE cells perform a number of tasks that are
critical to the health and function of photoreceptor cells. For
example, RPE cells convert vitamin A into a chemical derivative
that is necessary for vision. RPE cells shuttle oxygen and
nutrients from the blood supply to photoreceptor cells. RPE
cells also digest and recycle waste products created by
photoreceptor cells.
One major source of waste products is the outer segment tips that
photoreceptor cells shed during sleep. Outer segments, which
under the microscope resemble a roll of wrapped pennies, absorb
light and turn it into an electrical signal that is eventually
relayed to the brain. RPE cells digest these spent outer segment
tips and recycle their component vitamin A byproducts and fats
back to the photoreceptor cells. The photoreceptor cell then
uses these recycled materials to replenish its outer segments.
This process results in a complete renewal of an outer segment
in about ten days.
The Mertk gene is thought to play an important role in this
continual renewal of outer segments. Researchers have known for
some time that in the RCS rat, RPE cells are unable to ingest
outer segments. The shed disks accumulate between the RPE and
photoreceptor cell layers and, starting at the age of 21 days,
the RCS rat experiences a rapid degeneration of photoreceptor
cells. More recent investigation suggests that the Mertk gene
encodes a protein that in some way allows the RPE cell to ingest
the spent outer segment tips from the photoreceptor cells.
Mutations in the Mertk gene prevent the RPE cell from ingesting
outer segment tips and recycling their renewable resources. This
accumulation of outer segments leads to rapid vision loss.
Mertk mutations in humans also lead to a rapid loss of vision.
RP patients with Mertk mutations experienced night blindness and
poor vision in early childhood, and by adulthood had only a small
island of central vision. Researchers will next determine how
common Mertk mutations are among patients with RP
2. Macular Degeneration
A team of researchers including Dr Kang Zhang of the Cleveland
Clinic Foundation and Dr Donald J. Zack of the Wilmer Eye
Institute at Johns Hopkins University and Dr Radha Ayyagan at the
University of Michigan Medical Centre reported that a mutation
in a single gene - the ELOVL4 gene - causes two different forms
of macular degeneration: Stargardt-like macular dystrophy and
autosomal dominant macular dystrophy. Although Stargardt-like
macular dystrophy usually has an earlier onset and is the more
severe of the two, both diseases result in loss of central vision
and acuity in childhood or early adulthood. This new finding
suggests that since the same mutation in the ELOVL4 gene can
cause either disease, other genes may modify the severity and
course of the disease.
3. Usher syndrome type 1D
In an article published in the January 2001 issue of Nature
Genetics, Foundation researcher Dr Andreas Gal and colleagues
describe the discovery of genetic mutations causing Usher
syndrome type 1D. Usher syndrome is an autosomal recessive
disease that causes moderate to severe hearing loss and retinal
degeneration from RP. There are three types of Usher syndrome
based on the severity and onset of clinical symptoms of the
disorder. Usher type 1 is the most severe form of the disease.
Scientists believe there could be as many as ten genes containing
mutations that cause Usher syndrome. Foundation researchers have
made three such discoveries in the past five years, uncovering
gene mutations causing Usher syndrome 1B, 2A and most recently
1C.
NEWS FROM THE UNIVERSITY OF OTAGO RESEARCH GROUP From Dr Marion
Maw
Colorado Conference a stimulating experience. Red rock mountains
with trees in autumn colours were the backdrop for the recent
IXth International Symposium on Retinal Degeneration. A
grant-in-aid from Retina New Zealand enabled masters student
Ariana Hemara-Wahanui to attend this conference and to present
results to date from her thesis project. Ariana says that
meeting Dr John Heckenlively, author of Retinitis Pigmentosa, the
textbook she refers to constantly for her research was a major
highlight of the welcoming reception. The first session
encompassed new genes and loci, where Dr Carolyn Hope and Ariana
spoke about their work in partnership with a large whanau on
clinical and genetic characterisation of an X-linked retinal
disorder. The talk was well received with questions and feedback
from the audience providing insight into the possible mechanism
responsible for the disorder. Other sessions provided exposure
to the multidisciplinary research that is being undertaken
throughout the world with the shared goal of understanding and
overcoming retinal disorders. Taking part in and learning from
this symposium was a wonderful experience and Ariana would like
to express her gratitude to Retina NZ for helping to make this
possible.
TYPES OF VITAMIN A
For the last few years many people have asked whether they should take
the recommended dose of 15,000 IU daily of vitamin A palmitate to slow
their eyesight loss by several years. Some doctors advise against it and
some believe that this will help. Whatever you decide to do, Retina NZ
advises that you check with your doctor first before taking it regularly,
do not take it if you are pregnant and get a check annually to make sure
that your liver is not being affected.
The following question and answer tells you why it should always
be vitamin A palmitate that you take if you believe that it will
help you prolong your sight if you have RP.
Q. What is the difference between vitamin A palmitate and
vitamin A retinol palmitate? And what are the benefits of the
latter one?
A. Vitamin A is a compound that is in the form of an alcohol.
The more chemical name for vitamin A is "retinol". Hence the
"ol" at the end of the word signifying that it is an alcohol.
"Palmitate" comes from the words "palmitic acid", a chemical
compound that is a long chain fatty acid. When retinol and
palmitic acid combine chemically they form retinol palmitate.
The palmitate form of vitamin A is more stable and less toxic
than the free alcohol. Therefore, the recommended form of
Vitamin A for RP patients is the palmitate form. In the gut, the
palmitic acid is slowly cleaved off of the alcohol, freeing it
to be moved into the eye. The palmitate form is simply a storage
form of vitamin A that is easier to take. (Gerald G. Chader,Ph.D,
M.D.hc).
FOUNDATION RESEARCHERS PUBLISH VITAMIN A SAFETY DATA
In 1993 Dr Eliot Berson and colleagues at the U.S. FFB Research
Centre, the Berman-Gund Laboratory for the Study of Retinal
Degenerations of Harvard Medical School, published results from
a clinical trial, which found that a daily dose of 15,000 IU of
vitamin A palmitate on average slowed the course of common forms
of retinitis pigmentosa (RP) including Usher syndrome Type II.
This clinical trial heralded vitamin A as the first sight-saving
treatment for RP.
Recently Dr Berson and colleagues published results of a 12-year
follow-up study evaluating the long term safety of vitamin A in
146 patients with RP who participated in the original vitamin A
clinical trial. These patients were otherwise healthy and
between the ages of 18 and 54. The daily doses of vitamin A
palmitate for this group of patients ranged between 16,349 IU and
24,318 IU.
After 12 years of supplementation, vitamin A blood levels
increased by 18%. However, all the patients in this follow-up
study had blood levels of vitamin A within the normal range. The
patients also showed no clinical symptoms or signs of liver
toxicity attributable to vitamin A. The study authors conclude
"Prolonged daily consumption of less than 25,000 IU of vitamin
A can be considered safe for that time and amount in this age
group".
While the long-term safety of vitamin A palmitate in healthy
adults is now better established, Dr Berson recommends that
before beginning the vitamin A therapy, patients consult their
physician to review their medical history and current health
status. As a precaution, patients should also have blood tests
to measure vitamin A levels and liver function tests prior to
beginning the treatment and annually thereafter. If liver
function tests reveal any abnormalities, cessation of vitamin A
would be expected to prevent any possible complications due to
vitamin A toxicity. This long-term safety study, published in
the April 1999 American Journal of Clinical Nutrition, now
provides patients and doctors with more complete medical
information regarding the safety of the vitamin A treatment for
RP.
RESEARCHERS STUDY POSSIBLE LINK BETWEEN ESTROGEN AND AMD By Robyn
Miller, President, U.S. FFB
Researchers are currently examining the possibility of a link
between estrogen production and the onset of age-related macular
degeneration (AMD) in women. Information gathered in recent
years indicates there is a higher incidence of AMD in women, and
that women who experience an earlier onset of menopause may be
at greater risk of developing the disease. Scientists pooled
data from three separate epidemiological studies, and concluded
the connection may be related to the duration of estrogen
production during a woman's lifetime. A woman who experiences
an early onset of menopause has fewer years of estrogen
production, and the medical community has been investigating
whether this puts her at risk for heart disease, osteoporosis,
and certain types of cancers. Now, medical researchers will
begin to monitor her risk of developing macular degeneration as
well.
The U.S. National Institute of Health currently supports a large,
three-part study of women's post-menopausal health issues called
the Women's Health Initiative (WHI). With the co-operation of
more than 100,000 women recruited in July 1998, and 40 clinical
centres and communities across the country, the WHI will study
these issues using various approaches over the next 8 to 12
years. One of the three parts of the WHI is a controlled
clinical trial, using hormone replacement therapy (HRT). More
than 50,000 women are enrolled in this clinical trial and they
have been separated into two groups. One group receives estrogen
supplements and the other receives a placebo, or sugar pill. As
part of the clinical trial programme, researchers in the Women's
Health Initiative - Sight Exam (WHI-SE) will monitor and compare
the development of macular degeneration between the two groups.
Clinical studies, including the WHI-SE, constitute just one of
the three parts of the WHI. The other two parts include an
observational study of a larger group of women that monitors
their health through surveys and questionnaires over a period of
years. The third group is a project aimed at public awareness
and community involvement in women's health issues.
Although women seem to be at higher risk for developing AMD, HRT
is only one of many research areas addressing the causes and risk
factors associated with macular degeneration. Further study in
all areas will hopefully reveal which factors cause the disease
and which may serve to prevent it in both men and women.
NEW CLINICAL TRIAL FOR WET AGE-RELATED MACULAR DEGENERATION (AMD)
By Robyn Miller, President U.S. FFB.
The abnormal blood vessels that form in wet AMD are usually
visible during a doctor's examination. However, sometimes they
are hidden beneath layers of tissue. When the vessels are hidden
the condition is referred to as occult choroidal
neovascularization (occult CNV). Because an ophthalmologist must
be able to see the blood vessels in order to treat with
traditional laser therapy, or photodynamic therapy, patients with
occult CNV are not suitable candidates for photodynamic therapy
or high-intensity laser treatment.
However, a new, experimental laser treatment for occult CNV is
now being evaluated in a large, multi-centre clinical trial.
This treatment, called Transpupillary Thermotherapy (TTT),
employs a low-powered laser that seems able to treat hidden blood
vessel growth. TTT works by slightly raising the temperature of
the retina to clot blood within these abnormal blood vessels.
The blood clots seal the blood vessels, thus preventing any
further leakage and subsequent damage to central vision.
Positive results from a pilot study completed by Dr Elias Reichel
at The New England Eye Centre at Tufts University paved the way
for this trial, which aims to further test the safety and
efficacy of TTT. In the pilot study, 15 participants received
the treatment and were then followed by a doctor for an average
time of one year. Of the 16 eyes that were treated, 19%
experienced a slight improvement in vision over a period of six
months to two years. All but a few of the patients, including
those that experienced a small decline in vision, actually showed
a dramatic reduction in the thickness of the retina - an
indication that the growth and leakage of new blood vessels had
stopped, at least temporarily.
COPING
DESIGNING YOUR KITCHEN - Part 2 By June Ombler
In the August 2000 Retina Newsletter, Heather Arthur gave people
with retinal degenerative disorders many useful things to
consider when designing their dream kitchen or renovating the one
they have now. No mention of dishwashers was made in this
article, so I would like to briefly tell you about a dishwasher
that I had a look at recently.
Many RP's say that the two things that most frequently cause them
injuries are open dishwasher doors and low occasional tables, as
they do not see them. People with RP lose their peripheral
vision first and even though they may be able to see quite
clearly what is straight ahead of them through their remaining
tunnel of vision, things at shin height are invisible. An open
dishwasher door is an accident waiting to happen. It happens
again and again, even though you know it is a hazard, as another
member of the family may forget to close it. RP's also get
memory lapses and forget to close the door while going away to
answer the phone or front door, etc. and "Ouch!!!!", they've done
it again!
Now there is a solution to this problem. It is the Fisher and
Paykel Quantum Dishdrawer. Having had a demonstration of the
single drawer model, I feel that it can be the solution to the
problem of injured shins and pride. Also, it can be used by a
totally blind person and those with macular degeneration without
difficulty. The only drawback is the price, which is more
expensive than most other dishwashers, but if you are building
a new home or fully renovating your existing one, the cost can
be built into the whole job.
What's different about the Quantum Dishdrawer?
* It slides open like an ordinary kitchen drawer for easier
access, improved visibility and more usable space. The inside
of the drawer is 40 cm deep, so it fits tall and awkward dishes
and saucepans. A single drawer means that you use only 4 and a
half litres of water per wash, thus saving half the energy and
detergent, so each meal can be taken care of immediately.
* It has easy to use controls. The front panel has only three
"one touch" controls which "beep". The secondary controls are
concealed inside the front of the drawer. There are five of
these which give a"beep" sound when pressed. Once you have
selected the programme you want to use, you simply close the
drawer and press the Start/Pause button on the front of the
machine. This will automatically provide you with the same
programme every time unless you change it.
*If you have a large household you may need a double drawer unit
in which both drawers can be operated independently of each
other, saving water and energy if you only have a small amount
to wash. The front of the drawers can be finished to look like
wood, laminates or panelling to suit your kitchen finish.
* When open, the Dishdrawer has no sharp edges or corners, as
these have been moulded to avoid injury.
* This dishwasher has a flow through detergent dispenser and easy
to clean waste filter. Removable wire baskets inside the drawer
also make for easy loading and cleaning.
FLASHING LIGHT FOR SAFETY AT NIGHT
As most members are no longer able to drive and many have night
blindness, this very small flashing light can be an important
safety device for you to wear when jogging, going out alone and
having to cross roads or intersections at night.
It is The DX-450 "Safety Flasher" and can be obtained from Dick
Smith Electronics outlets. The catalogue number is Y 1061 and
the price less than $10.00. You will also have to purchase two
triple AAA batteries, which have a usable life of approximately
300 hours. To install the batteries two screws have to be undone
and you may need a sighted person's help to do this.
The "Safety Flasher" is red in colour, lightweight, has an
adjustable Velcro strap so that it can be worn around the wrist,
ankle or upper arm. It can also be clipped on to your belt or
hat band. Easy to turn on and off, its bright red flashing light
is very visible at night. (Kay McKenzie)
WARNING ABOUT TV MAGNIFIERS
Please be aware that if TV magnifiers are placed in an area that
receives direct sunlight it may melt the TV. Heather Arthur,
RNZFB TDL Practice Adviser issued this warning after a client had
this problem. Susan, who sent this warning to
Heather, said that she had recently seen a client who this has
happened to and she adds she had brought the TV magnifier into
her office and whilst checking her Email the magnifier had caught
the light coming through the open blinds and started to catch the
carpet on fire!
This warning also applies to any magnifier, including magnifier
mirrors. "Sometimes people put their magnifier down on a table
or ledge and at that time the sun is nowhere near it, but as the
sun moves round later in the day this, too, could be a fire
risk", said Heather.
DO YOU NEED HELP OR ADVICE?
The Retina NZ Peer Support programme is free and confidential
service, operating nationwide. To make contact, telephone 0800
243 33 33, press 1 for General enquiries and then ask the call
centre operator to put you in touch with a Peer Supporter in your
area.
DO YOU NEED YOUR NEWSLETTER IN BRAILLE OR IN LARGE PRINT?
We are conducting a survey to see how many members would prefer
to read their newsletters in Braille or in large print. To date
we have not offered this choice.
If you would like to receive your newsletter in Braille, please
remember that you can at present receive it on disk or by email
if you have a computer with a speech synthesizer provided you
tick either of these boxes on your member renewal form. As it
is expensive to get the newsletter published in Braille, please
consider the above alternatives first.
We are also thinking of providing the newsletter in large print
to those who cannot read it in standard print or on their
computer screen. This also costs the Society a little more than
sending it out in standard print.
If you would like to receive future copies of the newsletter in
Braille or large print, please contact Janet Palmer, National
Secretary, Retina NZ Inc., and let her know. Her phone number
is (04) 476 7329. You can leave a message on her answer phone but
remember to give your name and address with your request. You
can also email her on retinanz@ihug.co.nz
SUBSCRIPTIONS BECOME DUE ON 1ST APRIL 2001:
This is an early reminder that your annual subscription becomes
due on 1st April 2001. With this newsletter you will find your
member renewal form which you can complete and return straight
away if you wish, to the Secretary, Retina NZ, P.O. Box 27-177,
Wellington.
However, please post date your cheque to 2nd April 2001. This
will avoid any confusion with last year's accounts.
Auckland Genetic Hotline
(Ask for Dr Julie McGaughran) 0800 476 123
Wellington Genetic Hotline 0508 364 436
Christchurch Genetic Hotline 0508 364 436
(South Island callers ask for
Dr Caroline Lintott)
Janet Palmer, National Secretary P.O. Box
27-177, Wellington Phone: (04) 389-1538 Fax: (04) 389-5254
Email: retinanz@ihug.co.nz
CLOSING DATE FOR RECEIPT OF ARTICLES FOR THE NEXT ISSUE IS FRIDAY 11
MAY 2001.
|